DOCSLIB.ORG

Total Synthesis of the Big Four Antibiotics and Related Antibiotics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Total Synthesis of the Big Four Antibiotics and Related Antibiotics The Journal of Antibiotics (2013) 66, 107–129 & 2013 Japan Antibiotics Research Association All rights reserved 0021-8820/13 www.nature.com/ja REVIEW ARTICLE Total synthesis of the big four antibiotics and related antibiotics Kuniaki Tatsuta The first total syntheses of a variety of antibiotics have been accomplished by using carbohydrates as a chiral source. The key target molecules were members of the ‘Big Four’ classes of antibiotics (macrolides, aminoglycosides, b-lactams and tetracyclines), naphthoquinone antibiotics and their related antibiotics. The Journal of Antibiotics (2013) 66, 107–129; doi:10.1038/ja.2012.126 Keywords: antibiotics; carbohydrates; enantiospecific synthesis; natural products; total synthesis INTRODUCTION In the present paper, the author introduces the dynamic as well as ‘Antibiotic’ was one of the greatest scientific discoveries in the 20th elegant parts of his total synthesis of big four antibiotics and related century and the masterpiece of the total synthesis of antibiotics and compounds, focusing not only on ‘art’ but also on the significance bioactive natural products is a display of beauty, achieving a status of of the total syntheses, and featuring his concept of ‘all begins from ‘art’ in organic chemistry. total synthesis’. Anybody can draw a picture, but pictures painted by famous painters such as van Gogh, Monet and Picasso are praised as ‘art’. At TOTAL SYNTHESIS OF MACROLIDE ANTIBIOTICS AND THE the present time, many chemists are able to synthesize natural RELATED MACROLACTONE ANTIBIOTICS products, even those having complicated structure, using advanced When a stone is thrown into a pond, several ripples are produced in organic chemistry. However, not all such synthesis is above the succession, gradually radiating outward from the point of entry until mundane and can thus be raised to the level of ‘art’. The author is of they finally cover the whole pond. The ‘stone’ in macrolide synthesis the opinion that ‘art’ is a sublimate of originality, and has inherent was the news that R B Woodward had begun the total synthesis of special characteristics, and, even in the 21st century, it should be erythromycin A (2) in 1973. His group including the author recognized as such. accomplished the total synthesis in 1981. Some ripples from this Among bioactive natural products, several antibiotics, termed as the point of origin are represented by Masamune’s methymycin synthesis ‘BigFour’,weretheforemostsubjectofresearchatthetimetheauthor in 1977, Corey’s erythronolide synthesis in 1978 and our syntheses of 1 1–6 started his study of antibiotic synthesis. As shown in Figure 1, they carbomycin B, leucomycin A3 (3) and tylosin (4) in 1977 and 1981. were the macrolides (oleandomycin (1), erythromycin A (2), leuco- mycin A3 (3), tylosin (4)), aminoglycosides (kanamycin A (5), The first total synthesis of 16-membered macrolide antibiotics apramycin (6)), b-lactams (thienamycin (7)) and tetracyclines (tetra- The first total syntheses of the 16-membered macrolide anti- 7 8,9 cycline (8)). The author’s group has fortunately succeeded in complet- biotics, A26771B (1980), carbomycin B (1980), leucomycin A3 ing the total syntheses of 102 diverse bioactive natural products, (josamycin, 1980),8,9 and tylosin (1982)10,11 were accomplished in our including the above-mentioned representatives of the big four anti- laboratories.1–6 These syntheses were based on the stereoselective biotics, and 95 of them represented the first total synthesis of the construction of the carbon skeletons from D-glucose as shown in respective compounds.2–6 It is noteworthy that most of optically active Figure 2. compounds have been synthesized efficiently using carbohydrates as The first total synthesis of tylosin (4) was accomplished by chiral sources, to help determine the absolute structure and to clarify coupling of the C1-C10 (13) and C11-C15 (14) segments derived their structure-activity relationships. The methodologies devised are from D-glucose, and the stereo- and regio-selective introduction of now established as the usual way in the natural product synthesis.2–6 the three sugar moieties (17, 19 and 22) (Figure 3).10,11 The The first total synthesis requires the creation of original synthesis C-methyl compound 9, derived from D-glucose, was converted into concepts and methodologies, including the definition of the absolute the unsaturated ester 10, which was transformed to the methyl structure of the bioactive natural products, as well as the verification ketone 13 through a Michael addition with lithiated methyl of their biological activities. methylthiomethyl sulfoxide to give the branched ester 12. This Research Institute for Science and Engineering, Waseda University, Tokyo, Japan Correspondence: Professor K Tatsuta, Research Institute for Science and Engineering, Waseda University, 3-4-1 Ohkubo, Shinjuku-ku, Tokyo 169-8555, Japan. E-mail: [email protected] Received 5 October 2012; revised 15 October 2012; accepted 24 October 2012 Total synthesis of big four antibiotics and related antibiotics K Tatsuta 108 O O O NH Me Me Me 2 HO O HO Me Me Me Me OH Me HO NH OH OH HO 2 N Me Me N Me Me Me OH O HO HO HO NH2 Me O O O Me O O O Me HO O Me H2N O O O O OMe HO O Me Me OMe Me Kanamycin A (5) O OH O OH OH Me Me O Me Oleandomycin (1) Erythromycin A (2) H2N OH HO HN HO OH O O Me O CHO NH H N 2 Me 2 O HO NH N Me 2 MeO HO HO O O O O OH Me Apramycin (6) Me Me O OAc Aminoglycoside Antibiotics O O Me Me Leucomycin A3 (3) O Me O Me Me Me CHO HO Me OH N H H H H Me Me OH Me N Me Me NH2 O Me HO S HO O O O O O OH N O Me O OMe Me OH OMe O OH CO2H OH O OH O NH O OH 2 Me Tylosin (4) Me Thienamycin (7) Tetracycline (8) Macrolide Antibiotics -Lactam Antibiotic Tetracycline Antibiotic Figure 1 Representatives of big four antibiotics. 1 O C O C O C HO 6 HO AcO AcO HO HO OMe OMe 4 Me OH Sug O Sug O Sug O O HO Me 6 OH 1 CHO 9 CHO O OHC OHC OHC Me 12 Me OH OH Me Me Me Me N Me O Me HO 1 O HO O 9 HO HO O O 4 O O MeO OH OH OMe Me 1 CHO OMe O 1 OH D-Glucose O OH Me Me OH Me 12 HO O Sug 4: Tylosin OH OH O O 15 O 6 OH Me Me Me Carbomycin Leucomycin A3 Tylosin Figure 2 Total synthesis of 16-membered macrolide antibiotics from D-glucose. addition of the lithiated reagent to the correct position from the aldehyde group. The ethylene acetal 16 was submitted to initial desired side was effectively assisted by the metal chelation between glycosylation with D-mycaminosyl bromide 17, yielding the the isopropylidene oxygen and the carboxyl oxygen of the transition b-glycoside 18 after methanolysis. The second glycosylation, state 11, to give only the natural configuration at C6, as expected. accomplished by our particular method,8,13 using the glycal of This step was the first key component in completion of the synthesis. mycarose 19 and 1,3-dibromo-5,5-dimethylhydantoin, to give the The aldehyde 14 was also derived from D-glucose through the 2-bromo-2-deoxy-a-glycoside 20 followed by deprotection and branched alcohol. Aldol condensation of 13 with 14 gave the debromination to afford de-mycinosyl tylosin (21). This product unsaturated keto-ester 15, which was transformed to the seco-acid, was also isolated from the natural sources.14 The third glycosylation, followed by lactonization according to Corey’s procedure12 to give a using the mycinosyl bromide 22 under Koenigs ÀKnorr conditions, tylonolide derivative 16, following formation of the acetal of the followed by deprotection, completed the total synthesis of tylosin (4). The Journal of Antibiotics Total synthesis of big four antibiotics and related antibiotics K Tatsuta 109 The first total synthesis of 14-membered macrolide antibiotics then cyclization by intramolecular Horner ÀEmmons reaction after The author’s group accomplished the first total synthesis of a esterification of the C1-C7 and C8-C14 segments, 27 and 28,which 14-membered macrolide antibiotic, oleandomycin (1)(Figure4).15,16 were derived from the enantiomeric intermediates 25 and 26.Thesugar As mentioned above, this is also based on the construction of the moieties 30 and 31 were regio- and stereoselectively introduced on the skeleton from carbohydrates, L-andD-rhamnosides, (23)and(24), and aglycone, oleandolide (29), to give oleandomycin (1). CO Me O 2 H H OH OBn Me H MeS CO Me O BnO OMe 2 O 5 OH OH Me O MeS Me OH O O OOLi O 1 Me Me Me HO 3 C O OH BnO O MeS S S OH 2 Me H Me D-Glucose 9 MeS BnO O n-BuLi 10 11 12 O O O Me 10 Me 10 MeO Me Me O 10 Me OH 11 Me 615 6 OMe + Me OMe 6 Me Me Me O O TrO H TrO O Tr O O OH 15 3 3 11 15 3 MeO 1 OH O OH OH O OH Me CO2Me 13 14 1 Me 15 16 O O Me O O N Br Me Me Me N CHO O Br O Me Me Me Me N Me N Me Me HO Me HO Me Tr O O O OH AcO O OH O Me HO 14 O O O Me O O β Me 3 α NMe OH Me 2 O OH O OH OH Br O AcO 17 Me Me 19 Me Me AcO X (Mycarose 20: X = Br (Mycaminose 18 21: X = H Moiety) Moiety) O Me CHO Me Me Me N Me O β Me HO Me HO O O O O O OH O Me OMe Me Br OMe O OH OH O AcO 22 Me Me MeO OMe (Mycinose 4: Tylosin Moiety) Figure 3 Total synthesis of tylosin.
Load more

Recommended publications
  • The Role of Nanobiosensors in Therapeutic Drug Monitoring
    Journal of Personalized Medicine Review Personalized Medicine for Antibiotics: The Role of Nanobiosensors in Therapeutic Drug Monitoring Vivian Garzón 1, Rosa-Helena Bustos 2 and Daniel G. Pinacho 2,* 1 PhD Biosciences Program, Universidad de La Sabana, Chía 140013, Colombia; [email protected] 2 Therapeutical Evidence Group, Clinical Pharmacology, Universidad de La Sabana, Chía 140013, Colombia; [email protected] * Correspondence: [email protected]; Tel.: +57-1-8615555 (ext. 23309) Received: 21 August 2020; Accepted: 7 September 2020; Published: 25 September 2020 Abstract: Due to the high bacterial resistance to antibiotics (AB), it has become necessary to adjust the dose aimed at personalized medicine by means of therapeutic drug monitoring (TDM). TDM is a fundamental tool for measuring the concentration of drugs that have a limited or highly toxic dose in different body fluids, such as blood, plasma, serum, and urine, among others. Using different techniques that allow for the pharmacokinetic (PK) and pharmacodynamic (PD) analysis of the drug, TDM can reduce the risks inherent in treatment. Among these techniques, nanotechnology focused on biosensors, which are relevant due to their versatility, sensitivity, specificity, and low cost. They provide results in real time, using an element for biological recognition coupled to a signal transducer. This review describes recent advances in the quantification of AB using biosensors with a focus on TDM as a fundamental aspect of personalized medicine. Keywords: biosensors; therapeutic drug monitoring (TDM), antibiotic; personalized medicine 1. Introduction The discovery of antibiotics (AB) ushered in a new era of progress in controlling bacterial infections in human health, agriculture, and livestock [1] However, the use of AB has been challenged due to the appearance of multi-resistant bacteria (MDR), which have increased significantly in recent years due to AB mismanagement and have become a global public health problem [2].
    [Show full text]
  • Allosteric Drug Transport Mechanism of Multidrug Transporter Acrb
    ARTICLE https://doi.org/10.1038/s41467-021-24151-3 OPEN Allosteric drug transport mechanism of multidrug transporter AcrB ✉ Heng-Keat Tam 1,3,4 , Wuen Ee Foong 1,4, Christine Oswald1,2, Andrea Herrmann1, Hui Zeng1 & ✉ Klaas M. Pos 1 Gram-negative bacteria maintain an intrinsic resistance mechanism against entry of noxious compounds by utilizing highly efficient efflux pumps. The E. coli AcrAB-TolC drug efflux pump + 1234567890():,; contains the inner membrane H /drug antiporter AcrB comprising three functionally inter- dependent protomers, cycling consecutively through the loose (L), tight (T) and open (O) state during cooperative catalysis. Here, we present 13 X-ray structures of AcrB in inter- mediate states of the transport cycle. Structure-based mutational analysis combined with drug susceptibility assays indicate that drugs are guided through dedicated transport chan- nels toward the drug binding pockets. A co-structure obtained in the combined presence of erythromycin, linezolid, oxacillin and fusidic acid shows binding of fusidic acid deeply inside the T protomer transmembrane domain. Thiol cross-link substrate protection assays indicate that this transmembrane domain-binding site can also accommodate oxacillin or novobiocin but not erythromycin or linezolid. AcrB-mediated drug transport is suggested to be allos- terically modulated in presence of multiple drugs. 1 Institute of Biochemistry, Goethe-University Frankfurt, Frankfurt am Main, Germany. 2 Sosei Heptares, Steinmetz Building, Granta Park, Great Abington, Cambridge, UK. 3Present
    [Show full text]
  • NARMS – EB 2000 Veterinary Isolates Fig. 18. Resistance Among Salmonella Serotypes for Isolates from Cattle*
    NARMS – EB 2000 Veterinary Isolates Fig. 18. Resistance Among Salmonella Serotypes for Isolates from Cattle* S. typhimurium (n=332)** S. montevideo (n=330) Amikacin 0.00% Amikacin 0.00% Amox-Clav 14.46% Amox-Clav 0.61% Ampicillin 66.87% Ampicillin 0.61% Apramycin 1.20% Apramycin 0.00% Cefoxitin 10.54% Cefoxitin 0.61% Ceftiofur 12.65% Ceftiofur 0.61% Ceftriaxone 0.00% Ceftriaxone 0.00% Cephalothin 13.25% Cephalothin 0.61% Chloramphenicol 39.46% Chloramphenicol 0.91% Ciprofloxacin 0.00% Ciprofloxacin 0.00% Gentamicin 3.31% Gentamicin 0.30% Kanamycin 38.86% Kanamycin 0.00% Nalidixic Acid 0.00% Nalidixic Acid 0.00% Streptomycin 66.57% Streptomycin 1.52% Sulfamethoxazole 66.87% Sulfamethoxazole 1.21% Tetracycline 66.57% Tetracycline 2.12% Trimeth-Sulfa 5.42% Trimeth-Sulfa 0.30% 0% 10% 20% 30% 40% 50% 60% 70% 80% 0% 1% 1% 2% 2% 3% **including copenhagen S. anatum (n=292) S. newport (n=185) Amikacin 0.00% Amikacin 0.00% Amox-Clav 1.71% Amox-Clav 80.00% Ampicillin 2.40% Ampicillin 80.54% Apramycin 0.00% Apramycin 0.00% Cefoxitin 1.37% Cefoxitin 77.84% Ceftiofur 1.37% Ceftiofur 80.00% Ceftriaxone 0.00% Ceftriaxone 2.16% Cephalothin 2.05% Cephalothin 77.84% Chloramphenicol 1.71% Chloramphenicol 81.62% Ciprofloxacin 0.00% Ciprofloxacin 0.00% Gentamicin 0.68% Gentamicin 7.57% Kanamycin 1.71% Kanamycin 7.57% Nalidixic Acid 0.34% Nalidixic Acid 0.00% Streptomycin 2.05% Streptomycin 82.70% Sulfamethoxazole 2.05% Sulfamethoxazole 74.05% Tetracycline 35.96% Tetracycline 83.24% Trimeth-Sulfa 0.34% Trimeth-Sulfa 25.41% 0% 5% 10% 15% 20% 25% 30% 35% 40% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% *all sources NARMS – EB 2000 Veterinary Isolates Fig.
    [Show full text]
  • Microbiological Profile of Telithromycin, the First Ketolide Antimicrobial
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE Paperprovided by 48Elsevier Disc - Publisher Connector Microbiological profile of telithromycin, the first ketolide antimicrobial D. Felmingham GR Micro Ltd, London, UK ABSTRACT Telithromycin, the first of the ketolide antimicrobials, has been specifically designed to provide potent activity against common and atypical/intracellular or cell-associated respiratory pathogens, including those that are resistant to b-lactams and/or macrolide±lincosamide±streptograminB (MLSB) antimicrobials. Against Gram- positive cocci, telithromycin possesses more potent activity in vitro and in vivo than the macrolides clarithromycin and azithromycin. It retains its activity against erm-(MLSB)ormef-mediated macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes and against Staphylococcus aureus resistant to macrolides through inducible MLSB mechanisms. Telithromycin also possesses high activity against the Gram-negative pathogens Haemophilus influenzae and Moraxella catarrhalis, regardless of b-lactamase production. In vitro, it shows similar activity to azithromycin against H. influenzae, while in vivo its activity against H. influenzae is higher than that of azithromycin. Telithromycin's spectrum of activity also extends to the atypical, intracellular and cell-associated pathogens Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae. In vitro, telithromycin does not induce MLSB resistance and it shows low potential to select for resistance or cross-resistance to other antimicrobials. These characteristics indicate that telithromycin will have an important clinical role in the Ahed empirical treatment of community-acquired respiratory tract infections. Bhed Clin Microbiol Infect 2001: 7 (Supplement 3): 2±10 Ched Dhed Ref marker Fig marker these agents. Resistance to penicillin, particularly among S.
    [Show full text]
  • In Vitro and in Vivo Study of Fosfomycin in Methicillin-Resistant Staphylococcus Aureus Septicaemia
    J. Ilyg., Camb. (1980), 96, 419-423 419 Printed in Great Britain In vitro and in vivo study of fosfomycin in methicillin-resistant Staphylococcus aureus septicaemia BY W. Y. LAU, C. H. TEOH-CHAN,* S. T. FAN AND K. F. LAU* Government Surgical Unit, Queen Mary Hospital, and * Department of Microbiology, University of Hong Kong {Received 15 October 19S5; accepted 12 December 19S5) SUMMARY Five hundred strains of methicillin-resistant Staphylococcus aureus were tested against various anti-staphylococcal agents. Vancomycin, fusidic acid and fosfo- mycin were found to be the most effective. Only 1 strain out of 500 was resistant to fosfomycin. Three patients with methicillin-resistant Staphylococcus aureus septicaemia were successfully treated by fosfomycin. We conclude that fosfomycin could be the drug of choice for methicillin-resistant Staphylococcns aureus infection. INTRODUCTION Outbreaks of methicillin-resistant Staphylococcus aureus (MRSA) infection are causing increasing problems in centres all over the world (Thompson & Wenzel, 1982; Editorial, 1983). There has been a gradual increase in the incidence of MRSA in our hospital in Hong Kong from 317 in 1982 (18-7% of all S. aureus isolated) to 511 in 1983 (32-7%) and 833 in 1984 (34-9%). In vitro, resistance of MRSA is often demonstrated to many anti-staphylococcal agents including the penicillins, first-generation cephalosporins, aminoglycosides, erythromycin, clindamycin and chloramphenicol (Peacock et al. 1981). Second- and third-generation cephalosporins also have poor activity in vitro (Thompson, Fisher & Wenzel, 1982) though many MRSA strains have been found to be susceptible to rifampicin, trimethoprim- sulphamethoxazole and fusidic acid (Watanakunakorn, 1983). However, clinical experience of treating serious staphylococeal infection with rifampicin and trimethoprim-siilphamethoxazole is limited (Guenther & Wenzel, 1984) and fully resistant organisms may emerge rapidly after exposure to fusidic acid in vitro and in vivo (Watanakunakorn, 1983).
    [Show full text]
  • Combination of Minocycline and Rifampicin Against Methicillin- and Gentamicin-Resistant Staphylococcus Aureus
    J Clin Pathol: first published as 10.1136/jcp.34.5.559 on 1 May 1981. Downloaded from J Clin Pathol 1981 ;34:559-563 Combination of minocycline and rifampicin against methicillin- and gentamicin-resistant Staphylococcus aureus E YOURASSOWSKY, MP VAN DER LINDEN, MJ LISMONT, F CROKAERT From the H6pital Universitaire Brugmann, Service de Biologie Clinique, 1020 Bruxelles, Belgique SUMMARY Methicillin- and gentamicin-resistant Staphylococcus aureus may remain sensitive to minocycline and to rifampicin. A study of growth curves has shown that at inhibitory concentrations (0-4 ,ug/ml), minocycline prevents the development of mutants resistant to rifampicin. Staphylococcus aureus resistant to methicillin and strains of different phage type were selected for this gentamicin is responsible for an increasing number of investigation. hospital infections, some of which are severe.1-7 A number of treatments have been suggested although Microbial strains vancomycin is often the only major antibiotic which Minocycline HCL (Cyanamid Benelux, batch no is active against these strains. However, it is necessary 7116B-172). Rifampicin (Lepetit, batch no P/4) copyright. to assess the effect of the "second choice" antibiotics. (solution in dimethyl formamide). The MICs of The risk of rapid development of resistance to minocycline (tube dilution method in Mueller Hinton rifampicin is well known,8 9 and in spite of the medium, inoculum 106 micro-organisms/ml) were excellent penetration particularly in polymor- 0-2 ,ug/ml for all the strains. Rifampicin showed phonuclear cells of this antibiotic,10 11 its use alone is minimal inhibitory activity in liquid medium up to contraindicated. Minocycline is active against Staph a concentration of 0-01 ,ug/ml.
    [Show full text]
  • Tetracycline and Sulfonamide Antibiotics in Soils: Presence, Fate and Environmental Risks
    processes Review Tetracycline and Sulfonamide Antibiotics in Soils: Presence, Fate and Environmental Risks Manuel Conde-Cid 1, Avelino Núñez-Delgado 2 , María José Fernández-Sanjurjo 2 , Esperanza Álvarez-Rodríguez 2, David Fernández-Calviño 1,* and Manuel Arias-Estévez 1 1 Soil Science and Agricultural Chemistry, Faculty Sciences, University Vigo, 32004 Ourense, Spain; [email protected] (M.C.-C.); [email protected] (M.A.-E.) 2 Department Soil Science and Agricultural Chemistry, Engineering Polytechnic School, University Santiago de Compostela, 27002 Lugo, Spain; [email protected] (A.N.-D.); [email protected] (M.J.F.-S.); [email protected] (E.Á.-R.) * Correspondence: [email protected] Received: 30 October 2020; Accepted: 13 November 2020; Published: 17 November 2020 Abstract: Veterinary antibiotics are widely used worldwide to treat and prevent infectious diseases, as well as (in countries where allowed) to promote growth and improve feeding efficiency of food-producing animals in livestock activities. Among the different antibiotic classes, tetracyclines and sulfonamides are two of the most used for veterinary proposals. Due to the fact that these compounds are poorly absorbed in the gut of animals, a significant proportion (up to ~90%) of them are excreted unchanged, thus reaching the environment mainly through the application of manures and slurries as fertilizers in agricultural fields. Once in the soil, antibiotics are subjected to a series of physicochemical and biological processes, which depend both on the antibiotic nature and soil characteristics. Adsorption/desorption to soil particles and degradation are the main processes that will affect the persistence, bioavailability, and environmental fate of these pollutants, thus determining their potential impacts and risks on human and ecological health.
    [Show full text]
  • A Sensitive Method for Direct Analysis of Impurities in Apramycin and Other Aminoglycoside Antibiotics Using Charged Aerosol
    - SO4 A Sensitive Method for Direct Analysis of Impurities in Apramycin and Other Aminoglycoside Antibiotics Using Charged Aerosol Detection Zhen Long1, Qi Zhang2, Yan Jin1, Lina Liang1, Bruce Bailey2, Ian Acworth2, Deepali Mohindra3 1 2 3 Thermo Fisher Scientific, Shanghai, China, Thermo Fisher Scientific, Chelmsford, MA, USA and Thermo Fisher Scientific, Sunnyvale, CA, USA Comparison of CAD and ELSD Detection Analysis of Other Aminoglycoside Antibiotics Overview Results Purpose: To develop a sensitive non-derivatization method for impurity assessment of Sample pre-treatment with SPE This method has also been applied to impurity analysis of an additional eleven apramycin sulfate and other aminoglycoside antibiotics. Sample pre-treatment with SPE SPE Column: Dionex OnGuard II A CAD and ELSD are both nebulization-based universal detection technologies. aminoglycoside antibiotics, including neomycin, gentamicin, kanamycin, streptomycin, Comparison between CAD and ELSD under the same chromatographic conditions tobramycin, amikacin, etimicin, netilmicin, sisomicin, ribostamycin and paromomycin. Methods: A 30min gradient method using hydrophilic interaction liquid chromatography Sample solvent: 80% 5mM ammonium formate, 20% acetonitrile Sulfate is a major interference for apramycin impurity assessment with a HILIC method. demonstrated that CAD is much more sensitive than ELSD. As shown in the Figure 5 shows impurity analysis of kenamycin, etimicin, ribostamycin and paromomycin with charged aerosol detection (HILIC-CAD) was developed for direct analysis of Sample: 220.6 mg/mL in 2 mL sample solvent Without sample cleanup, some early eluting impurities were found to be masked under chromatograms in Figure 4 and data summarized in Table 1, 16 impurities (S/N >3) were using the HILIC-CAD method.
    [Show full text]
  • We Have Reported That the Antibiotics Chloramphenicol, Lincomycin
    THE BIOGENESIS OF MITOCHONDRIA, V. CYTOPLASMIC INHERITANCE OF ERYTHROMYCIN RESISTANCE IN SACCHAROMYCES CEREVISIAE* BY ANTHONY W. LINNANE, G. W. SAUNDERS, ELLIOT B. GINGOLD, AND H. B. LUKINS BIOCHEMISTRY DEPARTMENT, MONASH UNIVERSITY, CLAYTON, VICTORIA, AUSTRALIA Communicated by David E. Green, December 26, 1967 The recognition and study of respiratory-deficient mutants of yeast has been of fundamental importance in contributing to our knowledge of the genetic control of the formation of mitochondria. From these studies it has been recognized that cytoplasmic genetic determinants as well as chromosomal genes are involved in the biogenesis of yeast mitochondria.1' 2 Following the recog- nition of the occurrence of mitochondrial DNA,3 4 attention has recently been focused on the relationship between mitochondrial DNA and the cytoplasmic determinant.' However, the information on this latter subject is limited and is derived from the study of a single class of mutant of this determinant, the re- spiratory-deficient cytoplasmic petite. This irreversible mutation is pheno- typically characterized by the inability of the cell to form a number of compo- nents of the respiratory system, including cytochromes a, a3, b, and c1.6 A clearer understanding of the role of cytoplasmic determinants in mitochondrial bio- genesis, could result from the characterization of new types of cytoplasmic mutations which do not result in such extensive biochemical changes. This would thus simplify the biochemical analyses as well as providing additional cytoplasmic markers to assist further genetic studies. We have reported that the antibiotics chloramphenicol, lincomycin, and the macrolides erythromycin, carbomycin, spiramycin, and oleandomycin selec- tively inhibit in vitro amino acid incorporation by yeast mitochondria, while not affecting the yeast cytoplasmic ribosomal system.7' 8 Further, these antibiotics do not affect the growth of S.
    [Show full text]
  • Ketek, INN-Telithromycin
    authorised ANNEX I SUMMARY OF PRODUCT CHARACTERISTICSlonger no product Medicinal 1 1. NAME OF THE MEDICINAL PRODUCT Ketek 400 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 400 mg of telithromycin. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Light orange, oblong, biconvex tablet, imprinted with ‘H3647’ on one side and ‘400’ on the other. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications authorised When prescribing Ketek, consideration should be given to official guidance on the appropriate use of antibacterial agents and the local prevalence of resistance (see also sections 4.4 and 5.1). Ketek is indicated for the treatment of the following infections: longer In patients of 18 years and older: • Community-acquired pneumonia, mild or moderate (see section 4.4). • When treating infections caused by knownno or suspected beta-lactam and/or macrolide resistant strains (according to history of patients or national and/or regional resistance data) covered by the antibacterial spectrum of telithromycin (see sections 4.4 and 5.1): - Acute exacerbation of chronic bronchitis, - Acute sinusitis In patients of 12 years and older: • Tonsillitis/pharyngitis caused by Streptococcus pyogenes, as an alternative when beta lactam antibiotics are not appropriateproduct in countries/regions with a significant prevalence of macrolide resistant S. pyogenes, when mediated by ermTR or mefA (see sections 4.4 and 5.1). 4.2 Posology and method of administration Posology The recommended dose is 800 mg once a day i.e. two 400 mg tablets once a day. In patients of 18 years and older, according to the indication, the treatment regimen will be: - Community-acquired pneumonia: 800 mg once a day for 7 to 10 days, Medicinal- Acute exacerbation of chronic bronchitis: 800 mg once a day for 5 days, - Acute sinusitis: 800 mg once a day for 5 days, - Tonsillitis/pharyngitis caused by Streptococcus pyogenes: 800 mg once a day for 5 days.
    [Show full text]
  • Thienamycin (Imipenem)
    1520 THE JOURNAL OF ANTIBIOTICS OCT. 1989 CONVERSION OF OA-6129 B2 INTO OA-6129 B2, a fermentation carbapenem product, (5i?,6^)-6-[(i?)- l -FLUOROETHYL]-7- into optically active 88617, an 8-fluorinated OXO- 3 -[(7V,Ar,Ar-TRIM ETHYL- carbapenem derivative which improved antimicro- CARBAMIMIDOYL)METHYL]THIO- bial activity and dehydropeptidase-I stability. l -AZABICYCLO[3.2.0]HEPT-2-ENE- Treatment of OA-6129B2 sodium salt 1 with 2-CARBOXYLIC ACID (88617)t /7-nitrobenzyl (PNB) bromide or pivaloyloxymethyl chloride in DMFgave /?NB ester 2 or pivaloyl- Takeo Yoshioka, AzumaWatanabe, oxymethyl (POM) ester 3 of OA-6129 B2 (Fig. 1). Noritaka Chida and Yasuo Fukagawa The two hydroxyl groups in the pantoyl moiety of OA-6129B2 were protected by isopropylidena- Central Research Laboratories, tion for differentiation from the C-8 hydroxyl Sanraku Incorporated, 4-9-1 Johnan, Fujisawa 251, Japan group. The protected compound4 or 5 was allowed to (Received for publication May 25, 1989) react with 1.2 equiv of diethylaminosulfur trifluoride (DAST)11} at -68°C in methylene chloride for 10 minutes. After the reaction mixture was diluted with Since the epoch-making discovery of thienamy- methylene chloride and washed with a saturated cin2), a numberof extensive studies have been carried aqueous sodium bicarbonate solution, silica gel out on the development of clinically useful car- column chromatography of the organic layer pro- bapenem compounds. As a result, formimidoyl- vided the desired fluorinated compound 6 or 7 thienamycin (imipenem) has recently been put on having a fluorine atom in the R configuration at C-8 the market as a combination drug (Primaxin)3) in 43 or 49% yield, respectively.
    [Show full text]
  • 1028 Subpart A—Susceptibility Discs
    § 460.1 21 CFR Ch. I (4±1±96 Edition) 460.137 Methicillin concentrated stock solu- Neomycin: 30 mcg. tions for use in antimicrobial suscepti- Novobiocin: 30 mcg. bility test panels. Oleandomycin: 15 mcg. 460.140 Penicillin G concentrated stock so- Penicillin G: 10 units. lutions for use in antimicrobial suscepti- Polymyxin B: 300 units. bility test panels. Rifampin: 5 mcg. 460.146 Tetracycline concentrated stock so- Streptomycin: 10 mcg. lutions for use in antimicrobial suscepti- Tetracycline: 30 mcg. bility test panels. Tobramycin: 10 mcg. 460.149 Tobramycin concentrated stock so- Vancomycin: 30 mcg. lutions for use in antimicrobial suscepti- bility test panels. The standard discs used to determine 460.152 Trimethoprim concentrated stock the potency shall be made of paper as solutions for use in antimicrobial suscep- described in § 460.6(d). Each antibiotic tibility test panels. compound used to impregnate such 460.153 Sulfamethoxazole concentrated stock solutions for use in antimicrobial standard discs shall be equilibrated in susceptibility test panels. terms of the working standard des- ignated by the Commissioner for use in AUTHORITY: Sec. 507 of the Federal Food, determining the potency or purity of Drug, and Cosmetic Act (21 U.S.C. 357). such antibiotic. SOURCE: 39 FR 19181, May 30, 1974, unless (b) Packaging. The immediate con- otherwise noted. tainer shall be a tight container as de- fined by the U.S.P. and shall be of such Subpart AÐSusceptibility Discs composition as will not cause any change in the strength, quality, or pu- § 460.1 Certification procedures for an- rity of the contents beyond any limit tibiotic susceptibility discs.
    [Show full text]